Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C
© The Author(s) 2016
Received: 12 March 2016
Accepted: 16 August 2016
Published: 23 August 2016
Serine–arginine rich splicing factor 2 (SRSF2) is a protein known for its role in RNA splicing and genome stability. It has been recently discovered that SRSF2, along with other splicing regulators, is frequently mutated in patients with myelodysplastic syndrome (MDS). The most common MDS mutations in SRSF2 occur at proline 95; the mutant proteins are shown to have different RNA binding preferences, which may contribute to splicing changes detected in mutant cells. However, the influence of these SRSF2 MDS-associated mutations on specific splicing events remains poorly understood.
A tetracycline-inducible TF-1 erythroleukemia cell line was transduced with retroviruses to create cell lines expressing HA-tagged wildtype SRSF2, SRSF2 with proline 95 point mutations found in MDS, or SRSF2 with a deletion of one of the four major domains of the protein. Effects of these mutants on apoptosis and specific alternative splicing events were evaluated. Cells were also treated with DNA damaging drugs for comparison. MDS-related P95 point mutants of SRSF2 were expressed and phosphorylated at similar levels as wildtype SRSF2. However, cells expressing mutant SRSF2 exhibited higher levels of apoptosis than cells expressing wildtype SRSF2. Regarding alternative splicing events, in nearly all examined cases, SRSF2 P95 mutants acted in a similar fashion as the wildtype SRSF2. However, cells expressing SRSF2 P95 mutants had a percent increase in the C5 spliced isoform of cell division cycle 25C (CDC25C). The same alternative splicing of CDC25C was detected by treating cells with DNA damaging drugs, such as cisplatin, camptothecin, and trichostatin A at appropriate dosage. However, unlike DNA damaging drugs, SRSF2 P95 mutants did not activate the Ataxia telangiectasia mutated (ATM) pathway.
SRSF2 P95 mutants lead to alternative splicing of CDC25C in a manner that is not dependent on the DNA damage response.
KeywordsSRSF2 Myelodysplastic syndromes RNA splicing CDC25C DNA damage response
It was recently discovered that SRSF2 is mutated in 10−15 % of patients with Myelodysplastic syndrome (MDS) and 25–30 % of patients with chronic myelomonocytic leukemia (CMML) [13–19]. Both of these diseases are aging-associated hematopoietic disorders that occur primarily in individuals over the age of 60 . The only effective long term treatment for either disease is a bone marrow transplant, which is often not possible to perform due to both the age of the patients and a high relapse rate in patients with advanced disease [21–24]. While the cause of these disorders is still unknown, alternative splicing in genes related to hematopoiesis and cell cycle regulation, such as CDC25C and RUNX1, have been found in patients with MDS or AML [25, 26]. For both of these diseases, patients with SRSF2 mutation have a miscoding of the proline at position 95 (P95) to a histidine, arginine, or leucine during the early stages of the disease. These mutations persist throughout the disease [18, 27]. Recent research has also shown that P95 mutations of SRSF2 affect the ability of SRSF2 to bind its canonical splicing enhancer sequences in RNA [28, 29]. In addition, the P95H mutation of SRSF2 can increase death of hematopoietic cells and cause changes in hematopoiesis [28, 30]. Results from these studies support the notion that these mutations of SRSF2 are involved in MDS pathogenesis. However, the mechanism for how these mutations lead to disease development is still unknown.
We have constructed stable cell lines expressing from a Tet-inducible promoter HA-tagged wildtype SRSF2 (SRSF2WT), HA-tagged SRSF2 with point mutations found in patients with MDS (SRSF2P95H, SRSF2P95L, and SRSF2P95R), and HA-tagged SRSF2 with in-frame deletions of each of the four major domains of the protein (SRSF2ΔRRM = deletion of the RNA recognition motif, SRSF2ΔHNG = deletion of the hinge region, SRSF2ΔRS = deletion of the arginine/serine-rich domain, and SRSF2ΔNRS = deletion of the nuclear retention signal) in TF-1 erythroleukemia cells (Fig. 1a). Our data showed that while the SRSF2P95R/L/H mutations did not affect cellular localization of the protein, they did increase early apoptosis and affect the alternative splicing of CDC25C towards a shorter isoform (CDC25C-C5) that has previously been shown to be upregulated when DNA is damaged in breast cancer cells exposing to sub-lethal levels of doxorubicin and cisplatin . Interestingly, we found SRSF2 mutant induced alternative splicing of CDC25C does not require activation of the DNA damage response pathway that is activated with cisplatin treatment.
The pRevTRE-SC35HA (SRSF2HA) tet-inducible plasmid was a gift from Xiang-Dong Fu’s lab at UCSD . Mutations of P95 were produced using site-directed mutagenesis with the QuikChange Kit (Agilent) with the following primers: SRSF2-P95X sense (5′-CTACGGCCGCCDCCCGGACTCAC-3′) and SRSF2-P95X antisense (5′-GTGAGTCCGGGHGGCGGCCGTAG-3′), where D is A, T, and G and H is A, T, and C . SRSF2 deletion mutants were produced using the InFusion cloning system (Clontech) and primers that overlapped the deletion sites: ΔRRM F1 (ATGTGGAGGGTATGACCTCCATGGCGCGCTACGGC), ΔRRM R1 (GCCGTAGCGCGCCATGGAGGTCATACCCTCCACAT), ΔHNG F1 (CGAGCTGCGGGTGCAAAGCCGCCGGGGACC), ΔHNG R1 (GGTCCCCGGCGGCTTTGCACCCGCAGCTCG), ΔRS F1 (CCCGGACTCACACCACCCTCCCCCAGTGTCCA), ΔRS R1 (TGGACACTGGGGGAGGGTGGTGTGAGTCCGGG), ΔNRS F1 (GGTCTCGGTCCAGGAGTCTCGAGTACCCATACGACG), ΔNRS R1 (CGTCGTATGGGTACTCGAGACTCCTGGACCGAGACC). SRSF2HA gene sequence was confirmed using Sanger sequencing. The lentiviral plasmid for expression of the reverse Tet transactivator protein (pHIV7-rtTA-V15), the plasmids for lentiviral packaging (pC-GP, pCMV-rev, pCMV-G), and the plasmids for retrovirus packaging (pCMV-GP and pCMV-G) were gifts from the lab of Jiing-Kwan Yee at City of Hope.
Production and transduction of lentivirus and retrovirus
For the rtTA lentivirus, 293T cells were transfected with pHIV7-rtTA, pC-GP-2, pCMV-rev2, and pCMV-G using calcium phosphate . After 48 h, cell supernatant was collected, filtered through a 0.45 µm filter, and precipitated in a 10 % PEG solution overnight at 4 °C. Virus was then concentrated by centrifuging the PEG solution 30 min at 2000×g. Supernatant was decanted and virus pellet was resuspended in the remaining solution. Virus was tittered on HT1080 cells by G418 resistance. TF-1 cells were transduced with rtTA lentivirus at an MOI of 0.003 for 48 h and then diluted to single cells and plated in 96-well plates for G418 selection. Single clones were collected and assayed for doxycyline induction potential. Clone #6 was chosen as the TF-1 TetON parental cell line.
For the SRSF2HA retroviruses, 293T cells were transfected with the respective pRevTRE-SRSF2HA plasmid, pCMV-GP, and pCMV-G sing calcium phosphate transfection. After 48 h, virus was collected as above. Virus was tittered on HT1080 cells by hygromycin B selection. TF-1 TetON cells were transduced with resulting retroviruses at an MOI of 0.1 for 48 h. Each group was then selected for 2 weeks using hygromycin B to produce the TF-1 TetON SRSF2HA cell lines.
cDNA synthesis and RT-PCR
1 × 106 cells were pelleted and resuspended in 100 µl Trizol. After 5 min incubation, 100 μl 100 % EtOH was added and RNA was isolated using Direct-zol kit (Zymo Research). 1 µg RNA was used for cDNA synthesis using either SuperScript III RT (Invitrogen) or PrimeScript RT (Clontech). Each RT-PCR reaction contained 10 μl 2× Taq (BioPioneer), 0.5 µM each primer, and 1 μl cDNA. Primer list and reaction conditions can be found in Additional file 1: Table S1.
Western Blot Analysis
1 × 106 cells were washed 1× with PBS and then resuspended in 50 µl dH20. 50 µl 2× Laemmli buffer, pre-warmed to 85 °C, was added to each sample. Samples were incubated 10 min at 95 °C. Samples were then aliquoted and flash frozen in liquid nitrogen to be stored at −80 °C. For SDS-PAGE, samples were diluted 3.5-fold using 1× Laemmli buffer, and 7 μl was loaded per lane. Following SDS-PAGE, proteins were transferred to PVDF membrane. The membranes were blocked for 1 h at RT with either 5 % (w/v) nonfat dry milk in TBST (50 mM Tris–Cl, pH 7.5. 150 mM NaCl, 0.1 % Triton X-100) or 3 % (w/v) BSA in TBST. Membranes were washed 3× with TBST. Primary antibodies [rabbit anti-HA tag (Abcam; ab9110; 1:10,000), mouse anti-GAPDH (Invitrogen; ZG003; 1:5000), mouse anti-SR proteins [1H4] (Santa Cruz Biotech; sc-13,509; 1:200), rabbit anti-CDC25C [E303] (GeneTex; GTX61135; 1:500), rabbit anti-phospho CHK2 (Cell Signaling Technology; 2661; 1:2000), and mouse anti-phospho p53 [16G8] (Cell Signaling Technology; 9286; 1:500)] were diluted as stated in TBST and incubated overnight at 4 °C. Membranes were washed 3× with TBST. Secondary antibodies [goat anti-rabbit IgG-IRDye 680LT (Li-Cor; 926-68021; 1:20,000), goat anti-mouse IgG-IRDye 800CW (Li-Cor; 926-32,210; 1:20,000), goat anti-rabbit-HRP (BioRad; 170–6515; 1:3000), and goat anti-mouse-HRP (BioRad; 170–6516; 1:3000)] were diluted as stated in TBST and incubated with the membranes for 4 h at RT. Membranes were washed 3×, 5 min each wash, and subsequently scanned with an Odyssey machine (for Li-Cor secondaries) or exposed to X-ray film (for HRP secondaries).
1 × 107 cells were pelleted for 5 min at 400×g. Supernatant was removed and cells were resuspended in a buffer containing 50 mM HEPES (pH 7.8), 3 mM MgCl2, 300 mM NaCl, 1 mM DTT, 0.1 mM PMSF, 1X Halt™ Protease Inhibitor Cocktail (Thermoscientific), 5 mM NaF, 2 mM NaVO3, 0.5U/µl DNase I, and 5U/µl benzonase. Samples were incubated at 4 °C for 1 h with constant rotation, after which samples were centrifuged for 3 min at 4 °C, 10,000×g. Supernatant was added to 50 μl anti-HA agarose beads (Sigma) and total volume was brought to 200 μl with TBS. Samples were incubated overnight at 4 °C with constant end-over-end rotation. Agarose beads were pelleted for 10 s at 16,000g, and supernatant was removed as the unbound fraction. Pellet was washed 5× with TBST. Samples were eluted by incubating agarose beads with 50 µl 1 mg/ml HA peptide (ThermoFisher Scientific) at 30 °C for 15 min. Eluate was assayed by Western blot.
Glass coverslips (Fisher Scientific; 22 × 22–1.5) were incubated with 0.01 % poly-l-lysine (Sigma) for 10 min. Poly-l-lysine solution was removed and coverslips were air-dried. 2 × 105 cells were incubated on coverslips 1 h at 37 °C. Coverslips were washed 2× with PBS. Cells were fixed by incubating coverslips with 4 % (w/v) paraformaldehyde in PBS for 20 min at RT. Coverslips were then washed 2× with PBS and incubated 15 min at RT with 0.1 % (v/v) Triton X-100 in PBS. Cells were blocked by incubating coverslips overnight at 4 °C in 10 % (v/v) FBS in PBS. Coverslips were incubated with primary antibodies [rabbit anti-HA tag (Abcam; ab9110), mouse anti-SC35 (Abcam; ab11826), and mouse anti-γH2AX (ab11174)] each diluted 1:100 in the blocking solution for 1 h at RT. Coverslips were washed 5× with PBS and then incubated 1 h at RT with secondary antibodies [goat anti-rabbit IgG-AF647 (Jackson ImmunoResearch; 111-605-003) and goat anti-mouse IgG-AF488 (Jackson ImmunoResearch; 115-545-003)] diluted 1:100 in the blocking solution. Coverslips were then washed 5× with PBS and incubated 10 min at RT with 1× CellMask Orange (LifeTechnologies). Coverslips were then washed 3× with PBS and mounted on glass slides using VectaShield Hardset Mounting media with DAPI (Vector Laboratories). Slides were incubated overnight at 4 °C before imaged using a Zeiss LSM 700 confocal microscope. Analysis for HA-tagged protein localization was done using Image-Pro Plus (Media Cybernetics). The whole cell area was outlined in the Cell Mask Orange channel image and copied into the HA protein channel image. The nucleus was outlined in the DAPI channel image and also copied into the HA protein channel image. The integrated optical density (IOD) was analyzed independently for the whole cell and nucleus. The IOD for the cytoplasm alone was calculated by subtracting the IOD for the nucleus from the IOD of the whole cell.
1 × 105 cells were washed 1× with PBS. Cells were stained for 15 min using FITC-Annexin V and PI from FITC Annexin V Apoptosis Kit I (BD Pharmigen). Samples were then analyzed on a Cyan FACS machine. Cells were considered to be apoptotic based upon positive FITC detection. The stage of apoptosis was determined by the level of PI staining of the FITC-positive cells. Early apoptosis lacked any PI staining. Middle apoptosis had positive, albeit low levels of, PI staining. Late apoptosis was defined by high levels of PI staining.
Cell proliferation assay
5 × 106 cells were stained on day 0 in 10 µM CFSE (carboxyfluorescein succinimidyl ester, Thermo Fisher Scientific) for 15 min at 37 °C. Each day including day 0, half of the cell culture was removed from the flask, washed 2× with PBS, fixed for 15 min in 4 % (w/v) paraformaldehyde in water, washed 2× with PBS, and stored at 4 °C in the dark. After all time points for a single biological replicate were collected, samples were analyzed on a Cyan FACS machine. Data are plotted by using CFSE log mean.
Cell cycle analysis
1 × 106 cells were washed 2× with PBS. Cells were resuspended in 500 µl ice-cold 80 % EtOH and incubated overnight at 4 °C. Cells were washed 2× with PBS, and resuspended in 0.25 % Triton X-100, 20 µg/ml PI (propidium iodide), and 0.1 ng/ml RNase A. Cells were incubated overnight at 4 °C. Samples were analyzed on a Cyan FACS machine. Data were analyzed using the cell cycle tool in FlowJo v6.
Characterization of SRSF2-HA-expressing cell lines
We started our study by engineering a TF-1 TetON cell line. The TF-1 cell line was chosen due to its classification as an erythroblast, allowing for inducible expression of an HA-tagged SRSF2 in a cell type similar to those commonly affected in MDS patients in order to examine phenotypic changes that may occur as a result of SRSF2 mutations. Furthermore, by PCR and Sanger sequencing, none of the common MDS-related mutations in U2AF1(S34), SF3B1(K700), or SRSF2(P95) were detected in the parental TF-1 cell line (data not shown).
We used site directed mutagenesis to produce eight different SRSF2 constructs: wildtype (SRSF2WT), each of the three MDS- and CMML-related point mutations (SRSF2P95H, SRSF2P95L, and SRSF2P95R), and four deletions for each of the primary domains of SRSF2 for comparison (SRSF2ΔRRM, SRSF2ΔHNG, SRSF2ΔRS, and SRSF2ΔNRS) (Fig. 1a).
In order to assay for transgene expression, each of the SRSF2 cell lines (WT, P95H, P95L, P95R, ΔRRM, ΔHNG, ΔRS, and ΔNRS) and the parental TF-1 TetON cell line were cultured for 48 h, both with and without induction using 2 μg/ml doxycycline. After 48 h, protein and RNA were isolated from each line. Western blotting using anti-HA antibodies detected the expression of HA-tagged proteins with the expected size for each construct upon doxycycline induction (Fig. 1b). A small amount of the HA-tagged protein was expressed from the minimal CMV promoter without doxycycline induction (Additional file 2: Figure S1). The expression levels for SRSF2ΔRRM, SRSF2ΔHNG, and SRSF2ΔRS were noticeably lower than others (Fig. 1b, c). qRT-PCR of the ectopically expressed SRSF2-HA mRNAs showed no significant differences in the RNA level between the WT and mutants (Fig. 1d). Therefore, it appears that a deletion of the RRM, HNG, or RS domain negatively affects protein stability and/or efficient translation.
Since the hinge region of SRSF1 is required for kinase docking , we wanted to determine whether the disease-related P95 mutations of SRSF2, which occur in the hinge region, would affect the phosphorylation level of SRSF2. To this end, we immunoprecipitated the HA-tagged SRSF2 using an antibody against the HA tag. Western blots of the immunoprecipitated samples showed that SRSF2P95H, SRSF2P95L, and SRSF2P95R were phosphorylated to the same level as SRSF2WT, as measured by anti-phospho-SR antibody (1H4 monoclonal antibody) while none of the deletion mutants showed detectable levels of phosphorylation (Fig. 1e, f).
Factors that can initiate an apoptotic signaling cascade, such as Fas, Fas-L, tumor necrosis factor-a, and tumor necrosis factor-related apoptosis initiating ligand, are upregulated in bone marrow cells of MDS patients [37, 38], and it is thought that this increase in apoptosis in the bone marrow may contribute to the cytopenias that are a hallmark of MDS . To assay our cell lines for changes in apoptosis, FITC-Annexin V and propidium iodide (PI) staining were used to determine apoptosis levels in each of the TF-1 cell lines (Additional file 3: Figure S2b). Without doxycycline induction, there was no significant difference in apoptosis levels between any of the cell lines (Fig. 2b). However, with the doxycycline-induced expression of any of the three P95 mutant SRSF2 transgenes, cells showed a significant increase in early/middle apoptosis as compared to the SRSFWT and parental TetON cell lines (Fig. 2c). This result suggests that SRSF2 P95 mutations may be pro-apoptotic. We also noticed that SRSF2ΔHNG, SRSF2ΔRS, and SRSF2ΔNRS expressing cells also showed an increase in early/middle apoptosis as compared to the control cell lines, whereas SRSF2ΔRRM showed no effect on apoptosis. We have also measured cell proliferation using CFSE staining. Upon staining, CFSE covalently binds intracellular molecules such as proteins, and as the cells divide the existing CFSE-bound proteins are redistributed to the daughter cells resulted in decreasing CFSE staining per cell. Thus, cell proliferation can be accurately measured by monitoring CFSE staining in cell culture . By using CFSE staining, we did not observe significant change of cell proliferation with any of the SRSF2 mutants (Additional file 3: Figure S2c). Thus, increased apoptosis in SRSF2P95H/L/R is consistent with increased apoptosis of MDS cells.
Alternative splicing changes
We next investigated whether any of the SRSF2 mutants would alter splicing of other mRNAs that have been previously shown to be affected by SRSF2. To begin with, E2F1-mediated overexpression of SRSF2 has been shown to promote alternative splicing of a set of apoptosis-related genes to their pro-apoptotic form . We assayed alternative splicing of BCL-X, caspase-8, and caspase-9 by RT-PCR. At 48 h post-induction, we did not observe significant changes in alternative splicing in any of the SRSF2-expressing TF-1 cell lines (Additional file 4: Figure S3). Next, we assayed splice variants of BAP1 and TRA2A, which are found to change in mouse fibroblasts upon SRSF2 knock out . We observed no significant splicing changes in these genes with doxycycline-induced overexpression of SRSF2WT or any of the SRF2 mutants in TF-1 cells (Additional file 5: Figure S4).
We then considered that this alternative splicing change may cause expression of a truncated CDC25C protein. Western blotting using an anti-CDC25C antibody, specific for the C-terminus of the protein, detected the ~60 kDa CDC25C C1 protein and an increased expression of a smaller protein isoform that corresponds to the expected ~45 kDa CDC25C C5 protein (Fig. 4d, e). This result indicated that expression of SRSF2P95H, SRSF2P95R, or SRSF2P95L causes a splicing change of CDC25C mRNA, whereas expression of the SRSF2 deletion mutants or the wild-type protein does not produce the alternative splicing change.
CDC25C alternative splicing and the DNA damage response
Since agents that activate the ATM-mediated DNA damage response cause a similar splicing change (elevated CDC25C C5/C1) as the MDS-associated SRSF2 mutants, we wondered whether these point mutants may also activated the ATM-mediated DNA damage response. To test this, we examined whether the phosphorylation of ATM substrates (p53, CHK2, and H2A.X [61–68]) increases in the drug-treated cells and/or in the SRSF2 mutant expressing cells. Cell lysates were analyzed using Western blotting for phospho-p53 and phospho-pCHK2. Treatment of the TF-1 TetON cell line with CIS, CPT, or TSA led to an increase in both phospho-p53 and phospho-CHK2 compared to untreated TF-TetON cells, as expected (Fig. 5e). However, ectopically expressing SRSF2 in TF-1 cells did not show a significant increase in phospho-p53 or phospho-CHK2 compared to doxycyline-treated TF-1 TetON, regardless of whether the SRSF2 was WT or a P95 mutant. We also tested levels of γH2A.X phosphorylation, a general marker for genome instability , in each of these cell lines. Again, CIS, CPT, and TSA treatment each increased γH2A.X levels while none of the SRSF2 cell lines had an increase in γH2A.X (Fig. 5e; Additional file 7: Figure S6). In addition, by propidium iodide staining, none of the MDS-related point mutants induced G2/M arrest (Additional file 8: Figure S7a). To test whether apoptosis played a role in CDC25C alternative splicing, we added caspase inhibitor zVAD to block apoptosis in cells expressing SRSF2-P95 mutants. The ratio between splice variant C5 and C1 increased when SRSF2-P95 mutant expression was induced as expected; however, the addition of zVAD had no observable effect on CDC25C alternative splicing regardless whether SRSF2-P95 mutant expression was induced or not (Additional file 8: Figure S7B, C). This result indicated that apoptosis, although occurred in SRSF2-P95 mutant cells, was not responsible for the CDC25C alternative splicing. Taken together, it appears that the induction of CDC25C alternative splicing by MDS-related SRSF2 point mutations does not require activation of classical ATM DNA damage response pathway.
Known functions of SRSF2 include regulation of constitutive and alternative splicing and maintenance of genome stability through the prevention of transcription-related R-loops [2, 3, 70]. Nearly half of all patients with MDS have mutation in a gene that regulates splicing. One of the most common mutations is the point mutation of proline 95 of SRSF2 to histidine, leucine, or arginine, which occurs in 15–20 % of all MDS patients. Recent research has shown that this mutation affects the RNA recognition specificity of SRSF2 and that the P95H mutation in a mouse model correlates with a phenotype similar to MDS [28–30]. However, the effect of SRSF2 mutation on distinct alternative splicing events remains poorly understood. In this study, we show that MDS-related SRSF2 mutants act similar to wildtype SRSF2 in many ways, including phosphorylation and splicing of a select group of alternative splicing events. However, there is an alternative splicing change in CDC25C that is unique to SRSF2P95 mutants. Chemotherapeutics that induce the classical ATM DNA damage response, including cisplatin, camptothecin, and trichostatin A, also induce an identical alternative splicing change in CDC25C.
Recent research has shown that various types of DNA damage can lead to post-translational modification of RNA-binding proteins, many of which have roles in the regulation of RNA splicing [71–75]. In fact, cisplatin treatment has been shown to cause increased translocation of SR protein kinases SRPK1 and SRPK2 to the nucleus leading to hyperphosphorylation of SRSF2 and reducing acetylation of SRSF2 . In addition, activation of ATM- or ATR-mediated DNA damage response pathway has been shown to result in multiple changes in specific alternative splicing events, such as alternative splicing of apoptotic genes (BCL-X and caspase-8) [11, 76], DNA damage response genes (CHK1 and CHK2) [77, 78], and regulators of RNA splicing itself (TRA2, U2AF1, SRSF2 and SRSF1) [79–82]. However, the full changes in alternative splicing and their consequences for the DNA damage response still remain largely unknown.
Although it is known that CDC25C alternative splicing occurs after treatment with genotoxic drugs, the affects of this alternative splicing on the DNA damage response (DDR) and cell fate is still undetermined. CDC25C protein undergoes various post-translation modifications during the DDR in order to either induce the G2/M checkpoint or apoptosis. One of the major post-translational modifications is phosphorylation at Ser216 by CHK2, which leads to interaction of CDC25C with the 14-3-3 complex and subsequent translocation of the CDC25C protein to the cytoplasm . Without CDC25C present in the nucleus to activate CDK1 by dephosphorylation at Tyr15, the cell enters G2/M arrest. The C5 isoform of CDC25C is upregulated during S phase, a cell cycle phase during which DNA repair frequently occurs due to DNA replication; however, the role of the C5 isoform in the S phase is not clear . The alternative splicing of CDC25C, and its related protein CDC25A, is notable because it occurs primarily in the region of each transcript that encodes for the regulatory domain of the protein while leaving the catalytic domain intact (Fig. 4a) . It is possible that alternative splicing of CDC25C, in conjunction with post-translational modification, plays an important regulatory role in cell fate after DNA damage. Interestingly, our results showed that the SRSF2 P95 point mutants cause the same alternative CDC25C splicing change without activating conventional DDR.
CDC25C is part of the commonly deleted region in 5q-syndrome, and effective treatment of 5q- syndrome with lenalidomide requires haploinsufficiency of CDC25C [48–52]. Furthermore, alternative splicing of CDC25C has already been observed in bone marrow samples from patients with MDS . In addition, mutations in DNA damage response genes, such as p53 (TP53) and ATM, are found in MDS patients without 5-q deletion , and MDS-related U2AF1 mutations lead to alternative splicing in the DNA damage response genes ATR and FANCA . Therefore, it appears that CDC25C may be recurrently misregulated in MDS through gene deletion, aberrant DNA damage response, or aberrant splicing factors like SRSF2-P95 mutants and U2AF1 mutants.
In conclusion, our data support a model where MDS-related SRSF2 mutants lead to alternative splicing of CDC25C that increases the percentage of the C5 isoform among all the CDC25C variants. This alternative splicing event can also be induced by cisplatin, camptothecin, or trichostatin A treatment. However, the SRSF2 point mutants do not lead to phosphorylation of CHK2 or p53, which is readily detected in the drug-treated cells. Therefore, SRSF2P95H/L/R-mediated CDC25C alternative splicing changes do not require activation of the classical ATM DDR. The mechanism of CDC25C alternative splicing and its downstream effects may be pertinent to the role of SRSF2′s point mutation in the development of myelodysplastic syndrome.
serine–arginine rich splicing factor 2
cell division cycle 25C
ataxia telangiectasia mutated
RNA recognition motif
serine–arginine rich domain
nuclear retention signal
chronic myelomonocytic leukemia
LS and RJL conceived the project; LS, JMS, and RJL designed experiments; LS performed experiments; LS, JMS, and RJL analyzed the data; and LS, JMS, and RJL wrote the paper. All authors read and approved the final manuscript.
We thank Xiang-Dong Fu of UCSD for plasmid pRevTRE-SC35HA (SRSF2HA) and Jiing-Kuan Yee of City of Hope for plasmids pHIV7-rtTA, pC-GP-2, pCMV-rev2, pCMV-G, and pCMV-GP.
The authors declared that they have no competing interests.
LS was supported in part by the H.N. & Frances Berger Foundation Fellowship and the Norman and Melinda Payson Fellowship. This work was supported by grants from the Beckman Research Institute to RJL, National Institutes of Health Grant R01-CA120954 to JMS, and by NIH Grant P30-CA033572 for shared research core facilities at City of Hope.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Li X, Manley JL. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell. 2005;122(3):365–78.View ArticlePubMedGoogle Scholar
- Xiao R, Sun Y, Ding JH, Lin S, Rose DW, Rosenfeld MG, Fu XD, Li X. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol. 2007;27(15):5393–402.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu XD. The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct Mol Biol. 2008;15(8):819–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Sollier J, Stork CT, Garcia-Rubio ML, Paulsen RD, Aguilera A, Cimprich KA. Transcription-coupled nucleotide excision repair factors promote R-loop-induced genome instability. Mol Cell. 2014;56(6):777–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, Xiao R, Burge CB, Fu XD. SR proteins collaborate with 7SK and promoter-associated nascent RNA to release paused polymerase. Cell. 2013;153(4):855–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Fu XD, Maniatis T. The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3′ splice site. Proc Natl Acad Sci USA. 1992;89(5):1725–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Caceres JF, Screaton GR, Krainer AR. A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 1998;12(1):55–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 1998;12(10):1409–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Cazalla D, Zhu J, Manche L, Huber E, Krainer AR, Caceres JF. Nuclear export and retention signals in the RS domain of SR proteins. Mol Cell Biol. 2002;22(19):6871–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Hall LL, Smith KP, Byron M, Lawrence JB. Molecular anatomy of a speckle. Anat Rec A Discov Mol Cell Evol Biol. 2006;288(7):664–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, Brambilla E, Gazzeri S, Eymin B. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 2011;30(3):510–23.View ArticlePubMedGoogle Scholar
- Ngo JCK, Chakrabarti S, Ding J-H, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu X-D, Ghosh G. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell. 2005;20(1):77–89.View ArticlePubMedGoogle Scholar
- Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013;88(3):201–6.View ArticlePubMedGoogle Scholar
- Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441–50.View ArticlePubMedGoogle Scholar
- Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.View ArticlePubMedGoogle Scholar
- Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronne L, Scourzic L, Chesnais V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012;119(14):3211–8.View ArticlePubMedGoogle Scholar
- Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–84.View ArticlePubMedGoogle Scholar
- Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Lin CT, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120(15):3106–11.View ArticlePubMedGoogle Scholar
- Federmann B, Abele M, Rosero Cuesta DS, Vogel W, Boiocchi L, Kanz L, Quintanilla-Martinez L, Orazi A, Bonzheim I, Fend F. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. Hum Pathol. 2014;45(12):2471–9.View ArticlePubMedGoogle Scholar
- Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42.View ArticlePubMedGoogle Scholar
- Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21):2662–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76(1):36–43.PubMedGoogle Scholar
- Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin Hematol. 1995;2(4):283–92.View ArticlePubMedGoogle Scholar
- Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(Suppl 1):S25–9.PubMedGoogle Scholar
- Caudill JS, Porcher JC, Steensma DP. Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk Lymphoma. 2008;49(5):989–93.View ArticlePubMedGoogle Scholar
- Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsuda K, Ishida F, Ito T, Nakazawa H, Miura S, Taira C, Sueki A, Kobayashi Y, Honda T. Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up. Leuk Res. 2012;36(11):1393–7.View ArticlePubMedGoogle Scholar
- Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, Raza A, Mukherjee S, Manley JL. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci USA. 2015;112(34):E4726–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Komeno Y, Huang YJ, Qiu J, Lin L, Xu Y, Zhou Y, Chen L, Monterroza DD, Li H, DeKelver RC, et al. SRSF2 is essential for hematopoiesis, and its myelodysplastic syndrome-related mutations dysregulate alternative pre-mRNA splicing. Mol Cell Biol. 2015;35(17):3071–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Albert H, Battaglia E, Monteiro C, Bagrel D. Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines. Mol Oncol. 2012;6(5):542–52.View ArticlePubMedGoogle Scholar
- Li MJ, Rossi JJ. Lentivirus transduction of hematopoietic cells. Cold Spring Harb Protoc. 2007;2007(5):pdb.prot4755.Google Scholar
- Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol. 1997;138(2):225–38.View ArticlePubMed CentralGoogle Scholar
- Li H, Bingham PM. Arginine/serine-rich domains of the su(wa) and tra RNA processing regulators target proteins to a subnuclear compartment implicated in splicing. Cell. 1991;67(2):335–42.View ArticlePubMedGoogle Scholar
- Hedley ML, Amrein H, Maniatis T. An amino acid sequence motif sufficient for subnuclear localization of an arginine/serine-rich splicing factor. Proc Natl Acad Sci USA. 1995;92(25):11524–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Misteli T, Caceres JF, Spector DL. The dynamics of a pre-mRNA splicing factor in living cells. Nature. 1997;387(6632):523–7.View ArticlePubMedGoogle Scholar
- Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98(10):3058–65.View ArticlePubMedGoogle Scholar
- Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103(1):176–88.View ArticlePubMedGoogle Scholar
- Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103(4):1075–82.View ArticlePubMedGoogle Scholar
- Lyons AB, Blake SJ, Doherty KV. Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom. 2013;9:9–11.Google Scholar
- Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J. SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs. EMBO J. 2001;20(7):1785–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem Sci. 1998;23(6):198–9.View ArticlePubMedGoogle Scholar
- Mayeda A, Screaton GR, Chandler SD, Fu XD, Krainer AR. Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements. Mol Cell Biol. 1999;19(3):1853–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Kongruttanachok N, Phuangphairoj C, Thongnak A, Ponyeam W, Rattanatanyong P, Pornthanakasem W, Mutirangura A. Replication independent DNA double-strand break retention may prevent genomic instability. Mol Cancer. 2010;9:70.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar A, Rai PS, Upadhya R, Vishwanatha Prasada KS, Rao BS, Satyamoorthy K. Gamma-radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines. Int J Radiat Biol. 2011;87(11):1086–96.View ArticlePubMedGoogle Scholar
- Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 2008;15(12):1815–23.View ArticlePubMedGoogle Scholar
- Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, Qiu J, Huang J, Yeo GW, Ares M Jr, Fu XD. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell. 2013;50(2):223–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Bunn HF. 5q- and disordered haematopoiesis. Clin Haematol. 1986;15(4):1023–35.PubMedGoogle Scholar
- Pedersen B, Kerndrup G. Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. Cancer Genet Cytogenet. 1986;23(1):61–75.View ArticlePubMedGoogle Scholar
- Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23(7):1252–6.View ArticlePubMedGoogle Scholar
- Jadersten M, Karsan A. Clonal evolution in myelodysplastic syndromes with isolated del (5q): the importance of genetic monitoring. Haematologica. 2011;96(2):177–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA. 2009;106(31):12974–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000;57(8–9):1229–35.View ArticlePubMedGoogle Scholar
- Colton SL, Xu XS, Wang YA, Wang G. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem. 2006;281(37):27117–25.View ArticlePubMedGoogle Scholar
- Mu XF, Jin XL, Farnham MM, Li Y, O’Neill C. DNA damage-sensing kinases mediate the mouse 2-cell embryo’s response to genotoxic stress. Biol Reprod. 2011;85(3):524–35.View ArticlePubMedGoogle Scholar
- Ryan AJ, Squires S, Strutt HL, Johnson RT. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 1991;19(12):3295–300.View ArticlePubMedPubMed CentralGoogle Scholar
- Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, Conti C, Nakamura AJ, Das BB, Nicolas E, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009;10(8):887–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Marinello J, Chillemi G, Bueno S, Manzo SG, Capranico G. Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation. Nucleic Acids Res. 2013;41(22):10110–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee JS. Activation of ATM-dependent DNA damage signal pathway by a histone deacetylase inhibitor, trichostatin A. Cancer Res Treat. 2007;39(3):125–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res. 2003;63(11):2891–7.PubMedGoogle Scholar
- Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281(5383):1674–7.View ArticlePubMedGoogle Scholar
- Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281(5383):1677–9.View ArticlePubMedGoogle Scholar
- Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene. 1999;18(28):4047–54.View ArticlePubMedGoogle Scholar
- Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998;282(5395):1893–7.View ArticlePubMedGoogle Scholar
- Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 2000;97(19):10389–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276(45):42462–7.View ArticlePubMedGoogle Scholar
- Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol. 2002;4(12):993–7.View ArticlePubMedGoogle Scholar
- Stiff T, O’Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004;64(7):2390–6.View ArticlePubMedGoogle Scholar
- Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma. 2009;118(6):683–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A, Hesley JA, Miller SC, Cromwell EF, Solow-Cordero DE, et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell. 2009;35(2):228–39.View ArticlePubMedPubMed CentralGoogle Scholar
- Beli P, Lukashchuk N, Wagner SA, Weinert BT, Olsen JV, Baskcomb L, Mann M, Jackson SP, Choudhary C. Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell. 2012;46(2):212–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Bennetzen MV, Larsen DH, Bunkenborg J, Bartek J, Lukas J, Andersen JS. Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics. 2010;9(6):1314–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Blasius M, Forment JV, Thakkar N, Wagner SA, Choudhary C, Jackson SP. A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1. Genome Biol. 2011;12(8):R78.View ArticlePubMedPubMed CentralGoogle Scholar
- Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol. 2012;14(3):318–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Mastrocola AS, Kim SH, Trinh AT, Rodenkirch LA, Tibbetts RS. The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J Biol Chem. 2013;288(34):24731–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Shkreta L, Michelle L, Toutant J, Tremblay ML, Chabot B. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem. 2011;286(1):331–40.View ArticlePubMedGoogle Scholar
- Best A, James K, Dalgliesh C, Hong E, Kheirolahi-Kouhestani M, Curk T, Xu Y, Danilenko M, Hussain R, Keavney B, et al. Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons. Nat Commun. 2014;5:4760.View ArticlePubMedPubMed CentralGoogle Scholar
- Paronetto MP, Minana B, Valcarcel J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol Cell. 2011;43(3):353–68.View ArticlePubMedGoogle Scholar
- Katzenberger RJ, Marengo MS, Wassarman DA. Control of alternative splicing by signal-dependent degradation of splicing-regulatory proteins. J Biol Chem. 2009;284(16):10737–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Filippov V, Filippova M, Duerksen-Hughes PJ. The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. Cancer Res. 2007;67(16):7621–30.View ArticlePubMedGoogle Scholar
- Solier S, Barb J, Zeeberg BR, Varma S, Ryan MC, Kohn KW, Weinstein JN, Munson PJ, Pommier Y. Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res. 2010;70(20):8055–65.View ArticlePubMedPubMed CentralGoogle Scholar
- Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015;27(5):644–57.View ArticlePubMedPubMed CentralGoogle Scholar
- Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace AJ Jr. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411(6833):102–7.View ArticlePubMedGoogle Scholar
- Wegener S, Hampe W, Herrmann D, Schaller HC. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol. 2000;79(11):810–5.View ArticlePubMedGoogle Scholar
- Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–7.View ArticlePubMedGoogle Scholar
- Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, Bradley RK. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25(1):14–26.View ArticlePubMedPubMed CentralGoogle Scholar